Early detection of lung cancer significantly improves survival rates. Yet only 27% of all lung cancers are diagnosed at Stages 1-2. This is partly due to the lack of highly accurate, non-invasive diagnostic imaging methods that can differentiate malignant cancers from benign lesions.
In this upcoming webinar, Earli’s experts will introduce the workflow that they use to engineer LNPs to deliver cancer-activated DNA vectors that produce synthetic biomarkers for cancer imaging. Unlike most gene therapy applications, transfection of a tiny fraction of tumor cells can often produce sufficient biomarker expression for diagnostic imaging, provided there is minimal expression in normal cells. This necessitates the development of nanoparticles that can deliver DNA to lung tumors.
Insights into the key challenge of preventing rapid clearance of LNPs by the liver and spleen to reach the tumor, and the delivery of DNA to the nucleus of the cell, will be outlined. Earli’s team will also share how the Sunscreen & Sunshine systems are utilized as part of their screening and development workflow to determine which LNPs should be moved forward for testing in animal models to solve these challenges.
Join this webinar for insights into:
• Strategies for creating nanoparticles that deliver DNA to lung tumors and avoid rapid clearance by the liver and spleen
• The benefits of being able to formulate using small genetic payloads and rapidly screen non-standard LNP compositions
• How unified fluidic systems allow seamless scaling from screening to medium and large-scale formulations for in vivo studies, ensuring formulation comparability across scales
3 окт 2024
